Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Palvella Therapeutics, Inc.

NASDAQ: PVLA · Life Sciences · 7 alerts · CIK 1583648

Share price
$144.60Close, Nov 16
Market cap
$2.11B
Shares outstanding
14.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Palvella Therapeutics, Inc. filings on SEC EDGAR ↗

8:02 AM ET 10-Q
Financial Results

Palvella Therapeutics Q3 2026 Results: Net Loss of $24.6M, Loss Widens

Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) filed its Q3 2026 10-Q following its 2024 merger with Legacy Palvella. The company is focused on developing its lead product candidate, QTORIN rapamycin, for rare skin diseases and reported 14,618,457 shares of common stock outstanding as of November 2, 2026.

Key figure
Net loss $24.6M
7:31 AM ET 8-K
Financial Results

Palvella Therapeutics Financial Results

Palvella Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance and Priority Review of its NDA for QTORIN™ rapamycin in microcystic lymphatic malformations. The company ended the quarter with $236.7 million in cash and is preparing for a potential U.S. commercial launch in the first half of 2027 following a February 28, 2027 PDUFA date.

Term
Q3 2026

“With the FDA’s acceptance of our NDA for QTORIN™ rapamycin in microcystic lymphatic malformations and granting of Priority Review, we believe we are closer than ever to bringing our first therapy to patients.”

Wes Kaupinen, Founder and Chief Executive Officer

“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN™ programs to approval, and build the leading company addressing serious, rare skin diseases and vascular anomalies.”

Wes Kaupinen, Founder and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.